Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) reported a decline in both revenue and net profit for the first half of the year, indicating potential challenges in the company's financial performance [1] Financial Performance - The company achieved an operating revenue of 1.63 billion yuan, a decrease of 1.30% compared to the same period last year [1] - The net profit attributable to shareholders was 268 million yuan, down 7.83% year-on-year [1] Product Portfolio - Fuyuan Pharmaceutical has a diverse product range, including formulations for cardiovascular, chronic kidney disease, dermatology, digestive system, diabetes, mental health, and gynecology [1] - Key products include Olmesartan Medoxomil Tablets, Telmisartan Tablets, Trimetazidine Hydrochloride Tablets, Atorvastatin Calcium Tablets, and various others [1] Medical Device Business - The company's medical device segment primarily focuses on humidified oxygen devices, with main products including disposable oxygen tubes [1]